Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)Austin Kim, Mark A. Murakami, Clare Phinney et al.|Blood|2025Cited by 4
Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)Austin I. Kim, Mark A. Murakami, Philippe Armand et al.|Blood|2024Cited by 2